| Anthony Gerard Johnson, MD | |
|
22 Charlotte Dr, New Orleans, LA 70122-2532 | |
| (504) 648-7956 | |
| Not Available |
| Full Name | Anthony Gerard Johnson |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 22 Charlotte Dr, New Orleans, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063522811 | NPI | - | NPPES |
| 1998028 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 020613 (Louisiana) | Primary |
| Entity Name | Louisiana State University School Of Medicine In New Orleans Faculty G |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477582526 PECOS PAC ID: 0244136448 Enrollment ID: O20031209000661 |
News Archive
Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.
The United States should pay close attention to how the United Kingdom carries out plans to assess a new drug's worth using factors that go beyond clinical and cost effectiveness, according to researchers at the Johns Hopkins Berman Institute of Bioethics.
The introduction of new standards to assess nutrition in children could lead to confusion and a cut in the numbers of malnourished children eligible for emergency feeding programmes, warn researchers in the British Medical Journal.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
› Verified 4 days ago
| Entity Name | South Central La Human Services Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104250265 PECOS PAC ID: 7810129871 Enrollment ID: O20140407001422 |
News Archive
Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.
The United States should pay close attention to how the United Kingdom carries out plans to assess a new drug's worth using factors that go beyond clinical and cost effectiveness, according to researchers at the Johns Hopkins Berman Institute of Bioethics.
The introduction of new standards to assess nutrition in children could lead to confusion and a cut in the numbers of malnourished children eligible for emergency feeding programmes, warn researchers in the British Medical Journal.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anthony Gerard Johnson, MD 22 Charlotte Dr, New Orleans, LA 70122-2532 Ph: (504) 648-7956 | Anthony Gerard Johnson, MD 22 Charlotte Dr, New Orleans, LA 70122-2532 Ph: (504) 648-7956 |
News Archive
Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.
The United States should pay close attention to how the United Kingdom carries out plans to assess a new drug's worth using factors that go beyond clinical and cost effectiveness, according to researchers at the Johns Hopkins Berman Institute of Bioethics.
The introduction of new standards to assess nutrition in children could lead to confusion and a cut in the numbers of malnourished children eligible for emergency feeding programmes, warn researchers in the British Medical Journal.
Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.
› Verified 4 days ago
Korak Sarkar, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2820 Napoleon Ave Ste 810, New Orleans, LA 70115 Phone: 504-894-2395 | |
Miriam Maite Sevilla Saez-benito, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1525 River Oaks Rd W, New Orleans, LA 70123 Phone: 504-818-1392 | |
Dr. Maurice David Gelder, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 5323 Coliseum Street, New Orleans, LA 70115 Phone: 504-899-4160 | |
Abdul Hafeez Khan, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 719 Elysian Fields Ave, New Orleans, LA 70117 Phone: 504-942-8101 Fax: 504-942-8242 | |
Dr. Lucido Luciano Ponce Mejia, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2020 Gravier St Fl 7, New Orleans, LA 70112 Phone: 504-568-6120 Fax: 504-568-6127 | |
Jennifer Velander, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1542 Tulane Avenue, 2nd Floor, New Orleans, LA 70112 Phone: 504-568-6004 | |
Dr. Joshua Sanderson, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1750 St. Charles Ave., Suite 609, New Orleans, LA 70130 Phone: 504-232-1087 |